A Phase 1/2 Study of HS-410 in Patients With Non-Muscle Invasive Bladder Cancer After TURBT

Stopped early · Phase 1/Phase 2 · Has a placebo group

Conditions studied: Bladder Cancer

In brief

Phase I/II study: Phase 1 is an open-label, safety study, patients who previously received 3-6 instillations of weekly intravesical Bacillus Calmette-Guerin (BCG) induction therapy (as standard of care) followed by low dose intradermal (1\*10\^6 cells) HS-410 monotherapy. Phase 2, patients will be randomized to one of three blinded (physician-patient), placebo-controlled groups and receive either intradermal placebo or low dose (1\*10\^6 cells) or high dose (1\*10\^7 cells) vesigenurtacel-L in combination with induction and maintenance intravesical BCG. Patients who do not receive BCG will be enrolled into an open-label, non-randomized group receiving high dose (1\*10\^7 cells) intradermal HS-410 monotherapy.

Key facts

Study ID

NCT02010203

Run by

Heat Biologics

People needed

104

Starts

2013-12-01

Expected to finish

2018-04-01

Last updated by the study team

2020-02-17

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Histologically or cytologically confirmed non-muscle invasive bladder cancer [Ta, T1 or Tis (CIS)] that has been removed by transurethral resection
• Either: (i) high-risk disease, defined as T1 and/or high-grade and/or CIS or (ii) intermediate-risk disease, defined as Ta low-grade with at least 3 of the following 4 risk factors: multiple tumors, tumor size > 3cm, early recurrence (<1 year from previous staging procedure), or recurrence with a frequency of more than once in any 12 month period
• Not have received bacillus Calmette-Guérin (BCG) or have completed previous BCG treatment > 12 months prior to the baseline staging procedure.
• Phase 2 Arms 1-3: Suitable to receive a 6-week course of BCG in the adjuvant setting within 6 weeks following TURBT. Phase 2 Arm 4: Suitable for monotherapy vaccine administration post-TURBT. For Phase 1 only: Has previously received 3-6 weekly doses of BCG.
• Adequate laboratory parameters

You may not qualify if…

• Human immunodeficiency virus (HIV) infection or immunodeficiency disorders, either primary or acquired
• Infections or intercurrent illness requiring active therapy
• Any condition requiring active steroid or other immunosuppressive therapy
• Active malignancies within the past 12 months except negligible risk of metastasis or death treated with expected curative outcome.
• Prostate pelvic radiation within the past 12 months
• Significant cardiac impairment
• Current alcohol or chemical abuse, or mental or psychiatric condition precluding protocol compliance
• Pregnant or nursing
• Allergy to soy, egg, or peanut products
• Receiving another investigational agent (30 day wash-out required prior to first dose)
• Neo-adjuvant therapy prior to baseline staging procedures for the current occurrence of non-muscle invasive bladder cancer
• Prior treatment with a cancer vaccine for this indication
• Prior vaccination with BCG for tuberculosis disease
• Prior splenectomy

Where it is running

• University of California at Los Angeles — Los Angeles, California, United States
• Skyline Urology — Sherman Oaks, California, United States
• Skyline Urology — Torrance, California, United States
• Urology Center of Colorado — Denver, Colorado, United States
• University of Chicago — Chicago, Illinois, United States
• First Urology — Jeffersonville, Indiana, United States
• Horizon Oncology Research — Lafayette, Indiana, United States
• University of Kansas Cancer Center — Westwood, Kansas, United States
• Johns Hopkins University — Baltimore, Maryland, United States
• University of Massachusetts — Worcester, Massachusetts, United States
• University of Minnesota — Minneapolis, Minnesota, United States
• Washington University School of Medicine — St Louis, Missouri, United States
• Montefiore Medical Center — The Bronx, New York, United States
• University of North Carolina Chapel Hill — Chapel Hill, North Carolina, United States
• Thomas Jefferson University — Philadelphia, Pennsylvania, United States
• Carolina Urologic Research Center — Myrtle Beach, South Carolina, United States
• Urology of North Texas — Dallas, Texas, United States
• MD Anderson Cancer Center — Houston, Texas, United States
• Urology of Virginia — Virginia Beach, Virginia, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.